Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 274

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination

Open access
Parikh, Sydel R., Campbell, Helen, Bettinger, Julie A., Harrison, Lee H., Marshall, Helen S, Martinon-Torres, Federico, Safadi, Marco Aurelio, Shao, Zhujun, Zhu, Bingqing, von Gottberg, Anne, Borrow, Ray, Ramsay, Mary E, Ladhani, Shamez N · 2020 · Journal of Infection

Abstract

Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is associated with high case fatality rates and serious life-long complications among survivors. Twelve serogroups are recognised, of which six (A, B, C, W, X and Y) are responsible for nearly all cases of invasive meningococcal disease (IMD). The incidence of IMD and responsible serogroups vary widely both geographically and over time. For the first time, effective vaccines against all these serogroups are available or nearing licensure. Over the past two decades, IMD incidence has been declining across most parts of the world through a combination of successful meningococcal immunisation programmes and secular trends. The introduction of meningococcal C conjugate vaccines in the early 2000s was associated with rapid declines in meningococcal C disease, whilst implementation of a meningococcal A conjugate vaccine across the African meningitis belt led to near-elimination of meningococcal A disease. Consequently, other serogroups have become more important causes of IMD. In particular, the emergence of a hypervirulent meningococcal group W clone has led many countries to shift from monovalent meningococcal C to quadrivalent ACWY conjugate vaccines in their national immunisation programmes. Additionally, the recent licensure of two protein-based, broad-spectrum meningococcal B vaccines finally provides protection against the most common group responsible for childhood IMD across Europe and Australia. This review describes global IMD epidemiology across each continent and trends over time, the serogroups responsible for IMD, the impact of meningococcal immunisation programmes and future needs to eliminate this devastating disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jinf.2020.05.079

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 62

  1. Dastouri, 2014, Complications of serogroup B meningococcal disease in survivors: a review, Infect Disord Drug Targets, 14, 205, 10.2174/1871526515999150320155614 · doi:10.2174/1871526515999150320155614
  2. Beebeejaun, 2020, Invasive meningococcal disease: timing and cause of death in England, J Infect doi, 2008
  3. 2019, Invasive meningococcal disease: Annual Epidemiological Report for 2017, ECfDPaC
  4. Campbell, 2019, Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis, J Infect, 78, 323, 10.1016/j.jinf.2018.11.004 · doi:10.1016/j.jinf.2018.11.004
  5. Beresford, 2017, Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines, Vaccine35, 3598, 10.1016/j.vaccine.2017.03.066 · doi:10.1016/j.vaccine.2017.03.066
  6. 2019, Meningococcal Disease
  7. Krone, 2019, Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017, Euro Surveil, l24
  8. 2019, Invasive Meningococcal Disease in Ireland, 2018, on HSE HSE
  9. 2019, Meningococcal B
  10. Knol, 2017, Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study, Lancet Public Health, 2, e473, 10.1016/S2468-2667(17)30157-3 · doi:10.1016/s2468-2667(17)30157-3
  11. Hong, 2018, Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France, J Infect, 76, 149, 10.1016/j.jinf.2017.10.015 · doi:10.1016/j.jinf.2017.10.015
  12. Soeters, 2019, University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018, Emerg Infect Dis, 25, 434, 10.3201/eid2503.181574 · doi:10.3201/eid2503.181574
  13. Fiorito, 2017, Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine, J Am Coll Health, 65, 294, 10.1080/07448481.2017.1285772 · doi:10.1080/07448481.2017.1285772
  14. Law, 2006, Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19), J Clin Microbiol, 44, 2743, 10.1128/JCM.00601-06 · doi:10.1128/jcm.00601-06
  15. Bettinger JAS M, Morris S, Le Saux N, Top K, Vaudry W, Halperin S, Tsang R, 2018. Poster P59. The effect of quadrivalent vaccination programs in Canada; September 23-28, 2018., abstr International Pathogenic Neisseria Conference (IPNC), Asilomar, USA.
  16. Langley, 2016, Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study, Vaccine34, 4046, 10.1016/j.vaccine.2016.06.025 · doi:10.1016/j.vaccine.2016.06.025
  17. Bettinger, 2013, The disease burden of invasive meningococcal serogroup B disease in Canada, Pediatr Infect Dis J, 32, e20, 10.1097/INF.0b013e3182706b89 · doi:10.1097/inf.0b013e3182706b89
  18. Safadi, 2015, The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations, Vaccine33, 6529, 10.1016/j.vaccine.2015.10.055 · doi:10.1016/j.vaccine.2015.10.055
  19. 2018, Regional Inform from SIREVA II, 2015. Data by country and by age Group on characteristics of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis isolates in invasive bacterial infections, on Organización Panamericana de la Salud
  20. 2019, Notifiable Diseases Information System – Sinan
  21. Bakira, 2018, Update on meningococcal disease and its prevention, Rev Hosp Niños, 60, 42
  22. 2019, Bacterial meningitis and meningococcal disease
  23. Chacon-Cruz, 2019, Pediatric meningitis due to Neisseria meningitidis, Streptococcus pneumoniae and Group B Streptococcus in Tijuana, Mexico: active/prospective surveillance, 2005-2018, Ther Adv Infect Dis, 6
  24. Tiffay, 2015, The Evolution of the Meningitis Vaccine Project, Clin Infect Dis 61 Suppl 5, S396, 10.1093/cid/civ594 · doi:10.1093/cid/civ594
  25. Nnadi, 2017, Large Outbreak of Neisseria meningitidis Serogroup C - Nigeria, December 2016-June 2017, MMWR Morb Mortal Wkly Rep, 66, 1352, 10.15585/mmwr.mm6649a3 · doi:10.15585/mmwr.mm6649a3
  26. 2016, WHO guidelines for the treatment of Neisseria gonorrhoea
  27. Shao, 2006, Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China, Lancet, 367, 419, 10.1016/S0140-6736(06)68141-5 · doi:10.1016/s0140-6736(06)68141-5
  28. Junhong, 2015, Epidemiological Characteristics of Meningococcal Meningitis and Switching Trend of Serogroups of Neisseria meningitidis in China, Chin J Vaccine Immun, 21, 2006
  29. Juhong, 2019, Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017, Chin J Prev Med, 53, 159
  30. Zhang, 2016, Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis, J Glob Health, 6, 10.7189/jogh.06.020409 · doi:10.7189/jogh.06.020409
  31. Zhou, 2013, Spread of Neisseria meningitidis serogroup W clone, China, Emerg Infect Dis, 19, 1496, 10.3201/eid1909.130160 · doi:10.3201/eid1909.130160
  32. Hu, 2014, Neisseria meningitidis serogroup W135 sequence type 11, Anhui Province, China, 2011-2013, Emerg Infect Dis, 20, 1236, 10.3201/eid2007.131138 · doi:10.3201/eid2007.131138
  33. Zhang, 2008, Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005, Clin Microbiol Infect, 14, 555, 10.1111/j.1469-0691.2008.01977.x · doi:10.1111/j.1469-0691.2008.01977.x
  34. Zhou, 2015, Clonal characteristics of invasive Neisseria meningitidis following initiation of an A + C vaccination program in China, J Infect, 70, 2005, 10.1016/j.jinf.2014.07.022 · doi:10.1016/j.jinf.2014.07.022
  35. Zhu, 2015, Sequence Type 4821 Clonal Complex Serogroup B Neisseria meningitidis in China, 1978-2013, Emerg Infect Dis, 21, 925, 10.3201/eid2106.140687 · doi:10.3201/eid2106.140687
  36. Shao, 2010, Neisseria meningitidis serogroup W135, China, Emerg Infect Dis, 16, 348, 10.3201/eid1602.090901 · doi:10.3201/eid1602.090901
  37. Zhu, 2020, Comparative genomic analyses of Chinese serogroup W ST-11 complex Neisseria meningitidis isolates, J Infect, 80, 54, 10.1016/j.jinf.2019.08.019 · doi:10.1016/j.jinf.2019.08.019
  38. Zhu, 2019, Comparative genomic analyses of Chinese serogroup W ST-11 complex Neisseria meningitidis isolates, J Infect doi
  39. Chen, 2008, A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China, Chin Med J (Engl), 121, 664, 10.1097/00029330-200804010-00017 · DOI
  40. Pan, 2014, The case of a new sequence type 7 serogroup X Neisseria meningitidis infection in China: may capsular switching change serogroup profile?, Int J Infect Dis, 29, 62, 10.1016/j.ijid.2014.07.022 · doi:10.1016/j.ijid.2014.07.022
  41. Zhu, 2017, Genetic Analysis of Neisseria meningitidis Sequence Type 7 Serogroup X Originating from Serogroup A, Infect Immun, 85, 10.1128/IAI.01019-16 · doi:10.1128/iai.01019-16
  42. Li, 2019, The molecular characteristics of Neisseria meningitidis serogroup Y clonal complex 23 first emerge in China, J Infect doi, 10.1016/j.jinf.2019.07.001 · doi:10.1016/j.jinf.2019.07.001
  43. Fukusumi, 2016, National surveillance for meningococcal disease in Japan, Vaccine34, 1999
  44. John, 2013, An overview of meningococcal disease in India: knowledge gaps and potential solutions, Vaccine31, 2731, 10.1016/j.vaccine.2013.04.003 · doi:10.1016/j.vaccine.2013.04.003
  45. Sinclair, 2010, The epidemiology of meningococcal disease in India, Trop Med Int Health, 15, 1421, 10.1111/j.1365-3156.2010.02660.x · doi:10.1111/j.1365-3156.2010.02660.x
  46. Taj, 2016, Detection of meningococcal meningitis in cerebrospinal fluid of patients with neurological disorders in government hospitals of Karachi, J Pak Med Assoc, 66, 1418
  47. Hossain, 2009, Increasing isolations of Neisseria meningitides serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh, 1999-2006, Am J Trop Med Hyg, 80, 615, 10.4269/ajtmh.2009.80.615 · doi:10.4269/ajtmh.2009.80.615
  48. 2019, Australia's notifiable diseases status, 2015: Annual report of the National Notifiable Diseases Surveillance System (NNDSS), Commun Dis Intell, 43, 1
  49. 2019, Meningococcal Disease
  50. 2019, Disease notification rates, Australia, 1991 to 2018 and year-to-date notifications for 2019, on Australian Government Department of Health
  51. 2018, Invasive Meningococcal Disease National Surveillance Report - With a focus on MenW - 31 March 2018, on Australian Government Department of Health
  52. Lahra, 2013, Australian Meningococcal Surveillance Programme annual report, 2012, Commun Dis Intell Q Rep, 37, E224, 10.33321/cdi.2013.37.34 · doi:10.33321/cdi.2013.37.34
  53. Lahra, 2014, Australian Meningococcal Surveillance Programme annual report, 2013, Commun Dis Intell Q Rep, 38, E301, 10.33321/cdi.2014.38.50 · DOI
  54. Lahra, 2016, Australian Meningococcal Surveillance Programme annual report, 2014, Commun Dis Intell Q Rep, 40, E221, 10.33321/cdi.2016.40.17 · doi:10.33321/cdi.2016.40.17
  55. Lahra, 2016, Australian Meningococcal Surveillance Programme annual report, 2015, Commun Dis Intell Q Rep, 40, E503, 10.33321/cdi.2016.40.57 · doi:10.33321/cdi.2016.40.57
  56. Martin, 2016, Rise in invasive serogroup W meningococcal disease in Australia 2013-2015, Commun Dis Intell Q Rep, 40, E454, 10.33321/cdi.2016.40.50 · doi:10.33321/cdi.2016.40.50
  57. 2019, NOVEMBER 2019 PBAC MEETING – POSITIVE RECOMMENDATIONS
  58. 2019, Meningococcal disease
  59. O'Hallahan, 2004, The strategy to control New Zealand's epidemic of group B meningococcal disease, Pediatr Infect Dis J, 23
  60. Safadi, 2017, Knowing the scope of meningococcal disease in Latin America, Rev Panam Salud Publica, 41, e118
  61. Tzeng, 2017, Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen, Proc Natl Acad Sci U S A, 114, 4237, 10.1073/pnas.1620971114 · doi:10.1073/pnas.1620971114
  62. Deghmane, 2017, Emergence of meningococci with reduced susceptibility to third-generation cephalosporins, J Antimicrob Chemother, 72, 95, 10.1093/jac/dkw400 · doi:10.1093/jac/dkw400

Cited by

See all 274

Metadata

Authors
Parikh, S. R., Campbell, H., Bettinger, J. A., Harrison, L. H., Marshall, H. S., Martinon-Torres, F., Safadi, M. A., Shao, Z., Zhu, B., von Gottberg, A., Borrow, R., Ramsay, M. E., & Ladhani, S. N.
Venue
Journal of Infection
Publisher
Elsevier BV
Published
2020-10
Volume
81
Issue
4
Pages
483-498
ISSN
0163-4453 (ISSN-L)
OpenAlex
W3033885385
Cited by
274
References
99
FWCI
20.25
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.